Year in review 2011: Asthma, chronic obstructive pulmonary disease and airway biology

Respirology

Volumn 17, Issue 3, 2012, Pages 563-572

  Knight, Darryl A ^a   Yang, Ian A ^b   Ko, Fanny W S ^c   Lim, T K ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

airway biology; asthma; chronic obstructive pulmonary disease

Indexed keywords

ALLERGEN; CYCLOPHILIN A; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HEAT SHOCK PROTEIN 27; LEBRIKIZUMAB; MOMETASONE FUROATE; OMALIZUMAB; PROTEINASE; ROFLUMILAST; TIOTROPIUM BROMIDE;

AIR POLLUTION; ANGIOGENESIS; APOPTOSIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GENETICS; HOSPITALIZATION; HUMAN; LUNG ENDOTHELIUM; LUNG FUNCTION; META ANALYSIS (TOPIC); NEUTROPHIL; NONINVASIVE VENTILATION; OPEN STUDY; PERSONALIZED MEDICINE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; VIRUS INFECTION; WEIGHT REDUCTION;

ASTHMA; DISEASE PROGRESSION; FEMALE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX; VIRUS DISEASES;

EID: 84859040593     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02126.x     Document Type: Review

References (95)

1. Australian Centre for Asthma Monitoring. Asthma in Australia 2011. AIHW Asthma Series no. 4. Cat. no. ACM 22. AIHW, Canberra, 2011.
2. Mathews RR, Hall WD, Vos T, et al,. What are the major drivers of prevalent disability burden in young Australians? Med. J. Aust. 2011; 194: 232-5.
3. Reddel HK, Taylor DR, Bateman ED, et al,. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59-99.
4. Lai CKW, Ko FWS, Bhome A, et al,. Relationship between asthma control status, the Asthma Control Test and urgent health-care utilization in Asia. Respirology 2011; 16: 688-97.
5. Oei SM, Thien FCK, Schattner RL, et al,. Effect of spirometry and medical review on asthma control in patients in general practice: a randomized controlled trial. Respirology 2011; 16: 803-10.
6. Chung KF, Zhang J, Zhong N,. Outdoor air pollution and respiratory health in Asia. Respirology 2011; 16: 1023-26.
7. Dennekamp M, Abramson MJ,. The effects of bushfire smoke on respiratory health. Respirology 2011; 16: 198-209.
8. Lawson JA, Dosman JA, Rennie DC, et al,. Relationship of endotoxin and tobacco smoke exposure to wheeze and diurnal peak expiratory flow variability in children and adolescents. Respirology 2011; 16: 332-9.
9. Holgate ST,. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J. Allergy Clin. Immunol. 2011; 128: 495-505.
10. Lötvall J, Akdis CA, Bacharier LB, et al,. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. Journal of Allergy and Clinical Immunology 2011; 127: 355-60.
11. Mcdonald VM, Vertigan AE, Gibson PG,. How to set up a severe asthma service. Respirology 2011; 16: 900-11.
12. Powell H, Murphy VE, Taylor DR, et al,. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983-90.
13. Kobayashi D, Tochino Y, Kanazawa H, et al,. Comparison of alveolar nitric oxide concentrations using two different methods for assessing small airways obstruction in asthma. Respirology 2011; 16: 862-8.
14. Hillas G, Kostikas K, Mantzouranis K, et al,. Exhaled nitric oxide and exhaled breath condensate pH as predictors of sputum cell counts in optimally treated asthmatic smokers. Respirology 2011; 16: 811-8.
15. Jayaram L, Chunilal S, Pickering S, et al,. Sputum zinc concentration and clinical outcome in older asthmatics. Respirology 2011; 16: 459-66.
16. Lau EMT, Cooper W, Bye PT, et al,. Difficult asthma and Churg-Strauss-like syndrome: a cautionary tale. Respirology 2011; 16: 180-1.
17. Rahman NM, Dobson M, Davies RJO,. Setting up a respiratory trials unit. Respirology 2011; 16: 64-8.
18. Price D, Musgrave SD, Shepstone L, et al,. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 2011; 364: 1695-707.
19. Mahut B, Peiffer C, Bokov P, et al,. Use of specific airway resistance to assess bronchodilator response in children. Respirology 2011; 16: 666-71.
20. Hall GL, Annese T, Looi K, et al,. Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand. Respirology 2011; 16: 639-44.
21. Grainge CL, Lau LC, Ward JA, et al,. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364: 2006-15.
22. Chowdhury BA, Seymour SM, Levenson MS,. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N. Engl. J. Med. 2011; 364: 2473-5.
23. Williams LK, Peterson EL, Wells K, et al,. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J. Allergy Clin. Immunol. 2011; 128: 1185-91.
24. Tantisira KG, Lasky-Su J, Harada M, et al,. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 2011; 365: 1173-83.
25. Kurashima K, Kagiyama N, Takayanagi N, et al,. Comparison of high-dose salmeterol/fluticasone and moderate-dose salmeterol/fluticasone plus low-dose mometasone in patients with severe persistent asthma. Respirology 2011; 16: 784-9.
26. Hanania NA, Alpan O, Hamilos DL, et al,. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 2011; 154: 573-82.
27. Busse WW, Morgan WJ, Gergen PJ, et al,. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 2011; 364: 1005-15.
28. Corren J, Lemanske RF, Hanania NA, et al,. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 2011; 365: 1088-98.
29. Jamrozik E, Musk AW,. Respiratory health issues in the Asia-Pacific region: an overview. Respirology 2011; 16: 3-12.
30. Bai C, Zhang J, Ou J-X,. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology 2011; 16: 1165-72.
31. Yoo KH, Kim YS, Sheen SS, et al,. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011; 16: 659-65.
32. Idolor LF, De Guia TS, Francisco NA, et al,. Burden of obstructive lung disease in a rural setting in the Philippines. Respirology 2011; 16: 1111-8.
33. Sakao S, Tatsumi K,. The importance of epigenetics in the development of chronic obstructive pulmonary disease. Respirology 2011; 16: 1056-63.
34. National Heart, Lung and Blood Institute, World Health Organization. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2010. [Accessed 8 Nov 2011.] Available from URL
35. MacDonald M, Beasley RW, Irving L, et al,. A hypothesis to phenotype COPD exacerbations by aetiology. Respirology 2011; 16: 264-8.
36. Hoffmeyer F, Raulf-Heimsoth M, Bruning T,. Exhaled breath condensate and airway inflammation. Curr. Opin. Allergy Clin. Immunol. 2009; 9: 16-22.
37. Borrill ZL, Roy K, Singh D,. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J. 2008; 32: 472-86.
38. Ko FW, Leung TF, Wong GW, et al,. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 79-86.
39. Zakharkina T, Koczulla AR, Mardanova O, et al,. Detection of microorganisms in exhaled breath condensate during acute exacerbations of COPD. Respirology 2011; 16: 932-8.
40. Hui DS, Ip M, Ling T, et al,. A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. Respirology 2011; 16: 532-9.
41. Zhang W, Case S, Bowler RP, et al,. Cigarette smoke modulates PGE2 and host defence against Moraxella catarrhalis infection in human airway epithelial cells. Respirology 2011; 16: 508-16.
42. Chang CL, Sullivan GD, Karalus NC, et al,. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology 2011; 16: 146-51.
43. Edwards L, Perrin K, Wijesinghe M, et al,. The value of the CRB65 score to predict mortality in exacerbations of COPD requiring hospital admission. Respirology 2011; 16: 625-9.
44. Steer J, Norman EM, Afolabi OA, et al,. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax 2012; 67: 117-21.
45. Xu W, Collet JP, Shapiro S, et al,. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am. J. Respir. Crit. Care Med. 2008; 178: 913-20.
46. de Voogd JN, Wempe JB, Koeter GH, et al,. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135: 619-25.
47. de Miguel Díez J, Barrera VH, Maestu LP, et al,. Prevalence of anxiety and depression among chronic bronchitis patients and the associated factors. Respirology 2011; 16: 1103-10.
48. Roberts CM, Stone RA, Lowe D, et al,. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011; 8: 354-61.
49. Van Gestel AJR, KOHLER M, STEIER JR, et al,. Cardiac autonomic dysfunction and health-related quality of life in patients with chronic obstructive pulmonary disease. Respirology 2011; 16: 939-46.
50. Cvejic L, Harding R, Churchward T, et al,. Laryngeal penetration and aspiration in individuals with stable COPD. Respirology 2011; 16: 269-75.
51. Singh B,. Impaired swallow in COPD. Respirology 2011; 16: 185-6.
52. Hattesohl ADM, Jörres RA, Dressel H, et al,. Discrimination between COPD with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology 2011; 16: 1258-64.
53. Stoller JK, Aboussouan LS,. A review of alpha-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2012; 185: 246-59.
54. Fukuchi Y, Fernandez L, Kuo H-P, et al,. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011; 16: 825-35.
55. Wang J, Jin D, Zuo P, et al,. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2011; 16: 350-8.
56. Hoshino M, Ohtawa J,. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology 2011; 16: 95-101.
57. Lee S-D, Hui DSC, Mahayiddin AA, et al,. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011; 16: 1249-57.
58. Puhan MA, Gimeno-Santos E, Scharplatz M, et al,. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD005305.
59. Ko FWS, Dai DLK, Ngai J, et al,. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology 2011; 16: 617-24.
60. Bourbeau J,. Preventing hospitalizations for COPD exacerbation: early pulmonary rehabilitation? Respirology 2011; 16: 579-80.
61. Lan C-C, Yang M-C, Lee C-H, et al,. Pulmonary rehabilitation improves exercise capacity and quality of life in underweight patients with chronic obstructive pulmonary disease. Respirology 2011; 16: 276-83.
62. Vogiatzis I, Terzis G, Stratakos G, et al,. Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV. Chest 2011; 140: 744-52.
63. Ko FW, Hui DS,. The lower the body weight for COPD patients, the more effective is pulmonary rehabilitation? Respirology 2011; 16: 187-9.
64. Heinemann F, Budweiser S, Jörres RA, et al,. The role of non-invasive home mechanical ventilation in patients with chronic obstructive pulmonary disease requiring prolonged weaning. Respirology 2011; 16: 1273-80.
65. Moodley Y, Manuelpillai U, Weiss DJ,. Cellular therapies for lung disease: a distant horizon. Respirology 2011; 16: 223-37.
66. Rawlins EL,. The building blocks of mammalian lung development. Dev. Dyn. 2011; 240: 463-76.
67. Akhabir L, Sandford AJ,. Genome-wide association studies for discovery of genes involved in asthma. Respirology 2011; 16: 396-406.
68. Cookson WO, Moffatt MF,. Genetics of complex airway disease. Proc. Am. Thorac. Soc. 2011; 8: 149-53.
69. Al Heialy S, McGovern TK, Martin JG,. Insights into asthmatic airway remodelling through murine models. Respirology 2011; 16: 589-97.
70. Leclere M, Lavoie-Lamoureux A, Lavoie JP,. Heaves, an asthma-like disease of horses. Respirology 2011; 16: 1027-46.
71. Holgate ST,. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol. Rev. 2011; 242: 205-19.
72. Looi K, Sutanto EN, Banerjee B, et al,. Bronchial brushings for investigating airway inflammation and remodelling. Respirology 2011; 16: 725-37.
73. Demkow U, van Overveld FJ,. Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment. Eur. J. Med. Res. 2010; 15 (Suppl. 2): 27-35.
74. Hu R, Ouyang Q, Dai A, et al,. Heat shock protein 27 and cyclophilin A associate with the pathogenesis of COPD. Respirology 2011; 16: 983-93.
75. Jouneau S, Khorasani N, Des P, et al,. EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD. Respirology 2011; 16: 705-12.
76. Zani ML, Tanga A, Saidi A, et al,. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem. Soc. Trans. 2011; 39: 1441-6.
77. Subramaniyam D, Hollander C, Westin U, et al,. Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. Respirology 2011; 16: 300-7.
78. Cho YJ, Ma JE, Yun EY, et al,. Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 2011; 16: 284-90.
79. Takahashi T, Suzuki S, Kubo H, et al,. Impaired endothelial progenitor cell mobilization and colony-forming capacity in chronic obstructive pulmonary disease. Respirology 2011; 16: 680-7.
80. Imaoka H, Punia N, Irshad A, et al,. Lung homing of endothelial progenitor cells in humans with asthma after allergen challenge. Am. J. Respir. Crit. Care Med. 2011; 184: 771-8.
81. Qiu W, Cho MH, Riley JH, et al,. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS ONE 2011; 6: e24395.
82. Zhang S, Wang C, Xi B, et al,. Association between the tumour necrosis factor-alpha-308G/A polymorphism and chronic obstructive pulmonary disease: an update. Respirology 2011; 16: 107-15.
83. Kunz LI, Lapperre TS, Snoeck-Stroband JB, et al,. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir. Res. 2011; 12: 34.
84. Sato M, Shibata Y, Kimura T, et al,. Immunohistochemical staining for transcription factor MafB in alveolar macrophages is correlated with spirometric measures of airflow limitation in smokers. Respirology 2011; 16: 124-30.
85. Machiya J, Shibata Y, Yamauchi K, et al,. Enhanced expression of MafB inhibits macrophage apoptosis induced by cigarette smoke exposure. Am. J. Respir. Cell Mol. Biol. 2007; 36: 418-26.
86. Zhang Y, Moffatt MF, Cookson WO,. Genetic and genomic approaches to asthma: new insights for the origins. Curr. Opin. Pulm. Med. 2012; 18: 6-13.
87. Jamrozik EF, Warrington N, McClenaghan J, et al,. Functional haplotypes in the PTGDR gene fail to associate with asthma in two Australian populations. Respirology 2011; 16: 359-66.
88. Kim TH, An SH, Cha JY, et al,. Association of 5-hydroxytryptamine (serotonin) receptor 4 (5-HTR4) gene polymorphisms with asthma. Respirology 2011; 16: 630-8.
89. Mitchell J, Dimov V, Townley RG,. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr. Opin. Investig. Drugs 2010; 11: 527-34.
90. Li X, Howard TD, Zheng SL, et al,. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J. Allergy Clin. Immunol. 2010; 125: 328-35.
91. Yang H, Dong H, Dai Y, et al,. Association of interleukin-13 C-1112T and G+2044A polymorphisms with asthma: a meta-analysis. Respirology 2011; 16: 1127-35.
92. Fu WP, Zhao ZH, Zhong L, et al,. Relationship between polymorphisms in the 5â leader cistron, positions 16 and 27 of the adrenergic beta2 receptor gene and asthma in a Han population from southwest China. Respirology 2011; 16: 1221-7.
93. Proud D,. Role of rhinovirus infections in asthma. Asian Pac. J. Allergy Immunol. 2011; 29: 201-8.
94. Kuo C, Lim S, King NJ, et al,. Rhinovirus infection induces expression of airway remodelling factors in vitro and in vivo. Respirology 2011; 16: 367-77.
95. Wood LG, Powell H, Grissell TV, et al,. Persistence of rhinovirus RNA and IP-10 gene expression after acute asthma. Respirology 2011; 16: 291-9.